Merluzzi V J, Walker M M, Williams N, Susskind B, Hadden J W, Faanes R B
Int J Immunopharmacol. 1982;4(3):219-24. doi: 10.1016/0192-0561(82)90051-0.
NPT 15392, a new immunomodulating compound related to inosine in structure and isoprinosine in action, enhances T-cell dependent immune responses. Antibody responses to sheep red blood cells are augmented two to threefold in mice receiving NPT 15392 while T-cell independent antibody responses to TNP-LPS are unaffected. NPT 15392 does not enhance or alter the number of clonable B cells. This drug also increases cytotoxic T-lymphocyte responses to allogeneic tumor cells but does not alter the number of cytotoxic precursor cells. Immature hematopoietic cell classes (clonable progenitor cells) were also monitored and found not to be influenced by NPT 15392.
NPT 15392是一种结构上与肌苷相关、作用上与异丙肌苷相关的新型免疫调节化合物，可增强T细胞依赖性免疫反应。在接受NPT 15392的小鼠中，对绵羊红细胞的抗体反应增强了两到三倍，而对TNP-LPS的非T细胞依赖性抗体反应则未受影响。NPT 15392不会增加或改变可克隆B细胞的数量。这种药物还可增强细胞毒性T淋巴细胞对同种异体肿瘤细胞的反应，但不会改变细胞毒性前体细胞的数量。还监测了未成熟造血细胞类别（可克隆祖细胞），发现其不受NPT 15392的影响。
